Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1501 + SHR-2005 in High-Risk NMIBC
NCT06588179Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-1501 and SHR-2005 in bladder cancer, sponsored by Fudan University. Primary endpoints: Incidence of dose limiting toxicities, Recommended Phase 2 dose and 2 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
SHR-1501SHR-2005
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06588179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588179.